



Repairing Membranes to Rescue Mitochondria in Degenerative Diseases

Problem: Degenerative Diseases

- Over 50 diseases** associated with protein misfolding: Alzheimer's (AD), Parkinson's (PD), Type II Diabetes (T2D), Amyotrophic Lateral Sclerosis (ALS), Huntington's (HD), many rare diseases.
- Huge burden:** 540M patients, up to 10 years of full-time care, 3.6 million deaths per year, USD 3 trillion associated costs, USD 100B drug market, growing rapidly with aging population.
- High unmet need:** Many symptomatic treatments, but still no safe and effective disease-modifying treatments that can stop disease progression.
- Common mechanism:** Misfolded protein oligomers form toxic pores that perforate cell and mitochondrial membranes, causing uncontrolled calcium influx, mitochondrial dysfunction, loss of homeostasis, progressive cell death and degeneration.

Solution: Amporin's Technology and USP

- First-in-Class drug platform:** Amporin is developing the first class of oral small molecule drugs that can block, dissolve, and degrade toxic pores within cell and mitochondrial membranes.
- Novel and unique Mode of Action:** Amporin's drugs protect and repair cell membranes to restore mitochondrial function, allowing diseased cells to fully recover and restore homeostasis.
- USP:** First potential class of oral disease-modifying drugs that can stop disease progression with rapid functional recovery in over 50 degenerative diseases associated with protein misfolding.
- Proof-of-Concept:** Complete recovery of neurological function with acute oral dosing in 2 established animal models.
- Vision:** Cure 6 major degenerative diseases with a simple pill.

Business and Development Plan

- R&D pipeline:** Targeting 6 degenerative diseases to deliver 1 new drug candidate per year, starting with Parkinson's disease.
- Out-licensing to Big Pharma** after rapid biomarker-based proof of functional recovery with acute oral dosing in Phase 1b/2a trials.
- Clinical PoC:** No need for big, long and costly trials to show delay in long-term disease progression with chronic dosing.

Company and Management Team

- Incorporated:** April 2024 in Basel, Switzerland.
- 3 co-founders:** Dr Kelvin Stott (CEO), Dr Hervé Schaffhauser (CSO), Prof Daniel Umbricht MD (CMO).
- >25 years each** in Pharma (Roche, Novartis, Merck, CSL), biotech, clinical practice, business consulting, and venture capital.

Funding and Investment Opportunity

- CHF 500K raised to date:** Founders (CHF 100K equity); Venture Kick (CHF 150K loan); Kickfund (CHF 100K loan); business angels (CHF 150K in loans).
- Raising CHF 3-5M seed funding** to deliver 3 optimized drug leads with *in vivo* proof of rapid functional recovery in AD, Diabetes and PD; partner/out-license AD and Diabetes drug programs; and start IND-enabling studies in PD.
- Exit by sale to Pharma:** Expect 50-100X exit multiple by 2032.
- Unique investment opportunity:** First-in-Class drug platform with multi-blockbuster potential to cure multiple degenerative diseases.

Contact


- Kelvin Stott, CEO:** kelvin.stott@amporin.com; +41 78 749 49 36
- Amporin Pharmaceuticals AG:** Tech Park, Hochbergerstrasse 60C, 4057 Basel, Switzerland.

Social and Economic Cost of Degenerative Diseases




Sources: www.who.int, www.cdc.gov, www.healthdata.org, www.alz.org, www.parkinson.org, www.idf.org

Amporin's Unique Approach: Targeting Toxic Pores



Potential for Rapid Functional Recovery with a Pill



Pipeline Development, Licensing and Financing Plan

